Mosanna Therapeutics

📍 Redwood City, United States🗓 Founded 2022👥 15 employees💰 Last funded Sep 2025
Biotechnology Research🌐 mosanna.com
Website LinkedIn
Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland.
3
Total investors
2
Early stage
1
Mid stage
0
Late stage
2022
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
Germany
1
Investor activity2023–2025 · investors recorded per year
2023220251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Mosanna Therapeutics?
Mosanna Therapeutics has 3 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage.
When did Mosanna Therapeutics last raise funding?
The most recent investment in Mosanna Therapeutics recorded on gritt.io was in September 2025.
When was Mosanna Therapeutics founded?
Mosanna Therapeutics was founded in 2022.
What industry is Mosanna Therapeutics in?
Mosanna Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Mosanna Therapeutics based?
Mosanna Therapeutics is headquartered in Redwood City, United States.